Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Looks To Resume Unannounced Inspections In India And China

Executive Summary

After lapsing due to COVID-19, an unannounced foreign inspection pilot program is on track to resume in 2022, “despite challenges and constraints of travel.”

You may also be interested in...



House User Fee Bill’s Inspections Provisions Would Add Layers Of Scrutiny Abroad

Inspection subsection would penalize high-quality sites in low-quality foreign regions with greater inspection frequency, while adding more surprise inspections and requiring greater internal FDA coordination to prevent quality issues from causing drug shortages.

House User Fee Bill’s Inspections Provisions Would Add Layers Of Scrutiny Abroad

Inspection subsection would penalize high-quality sites in low-quality foreign regions with greater inspection frequency, while adding more surprise inspections and requiring greater internal US FDA coordination to prevent quality issues from causing drug shortages.

US FDA Strengthens Inspection Capabilities With Pandemic Alternatives – And Travel Savings

Agency’s Office of Regulatory Affairs mines third-country EU inspections and remotely delivered documents while investing travel savings, redirecting field force and preparing for new post-pandemic travel challenges.

Related Content

Topics

UsernamePublicRestriction

Register

PS145384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel